EMJ Dermatology 7.1 2019

Experts explore 3-year clinical data on bimekizumab presented at the 2025 EADV and SHSA congresses, highlighting its durable and deep… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

Interview with David Fisher, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

Atopic dermatitis (AD) is a common, chronic inflammatory skin disease that presents heterogeneously across patients. It carries a… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.